Universities should not have to bow to research institutes, writes Debashis Gangopadhyay. Basic Sciences versus Applied Sciences Undermining humanities studies in schools will lead to a large number of science graduates in the market. This is a boon for multinational companies as profits will escalate — the cost of labour being lower. However, the danger to profits persist from another aspect. Students who study science out of their love for a subject are...

Apparently, people across the country, bridging class, caste and income divides, are deliberately ensuring that girls are simply not born. The child sex ratio of 914 girls per 1,000 boys is a tragic situation and a poor reflection on India’s growth and development. This is in spite of laws, schemes, relentless activism and media campaigns spanning three decades in support of the girl child. According to activists and economists, a...

Census 2011 data bring into the open Maharashtra’s terrible record in sex-selective abortions. In early June, Vijaymala Patekar, a mother of four girls, haemorrhaged to death at a hospital in Parli, Beed district, Maharashtra. She was reportedly in her second trimester of pregnancy. Her family had allegedly forced her to abort the foetus when they learnt it was a girl child. Sudam Munde, the doctor who performed the procedure, fled Parli but...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...

-The Indian Express India may not be a testing hub for Big Pharma. But informed consent must be non-negotiable Figures released by the World Health Organisation, which show that 10 Indian subjects of clinical field trials die every week, have rekindled concerns that this country has become a testing hub for Big Pharma. Ironically, the same figures deflate this persistent fear, revealing that only 1.5 per cent of global trials have been...